Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson

Last Updated: December 5, 2021

DrugPatentWatch Database Preview

Patent: 8,668,914

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,668,914
Title:Use of equol for treating skin diseases
Abstract: Equol (7-hydroxy-3(4\'hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5.alpha.-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol\'s biological properties. The significance of equol\'s ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies of skin and hair. Thus, equol can specifically bind DHT and prevent DHT\'s biological actions in physiological and pathophysiological processes affecting skin and hair.
Inventor(s): Lephart; Edwin Douglas (Orem, UT), Lund; Trent D. (St. Charles, IL), Setchell; Kenneth David Reginald (Cincinnati, OH), Handa; Robert J. (Phoenix, AZ)
Assignee: Brigham Young University (Provo, UT) Colorado State University Research Foundation (Fort Collins, CO) Children\'s Hospital Medical Center (Cincinnati, OH)
Application Number:12/533,169
Patent Claims:see list of patent claims

Details for Patent 8,668,914

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Smith & Nephew, Inc. SANTYL collagenase Ointment 101995 1965-06-04 ⤷  Try it Free 2022-07-24
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.